Table 2
Elevations in Liver Biochemical Tests Based on Thresholds
<Analysis Set>

Total Bilirubin > 2x ULN

Risk Risk Risk Difference Difference Difference PLT1 Т2 T1-PL T2-PL T2-T1 n/N (%) n/N (%) n/N (%) (95% CI) (95% CI) (95% CI) (N=355)(N=318)(N=326)(N=673)(N=681)(N=644)ALT > 3x ULN 9/355 (2.5%) 8/318 (2.5%) 11/326 (3.4%) -0.0 (-2.4 - 2.4)0.8 (-1.7 - 3.4)0.9 (-1.8 - 3.5)-1.3 (-7.0 - 4.3)> 5x ULN 53/318 (16.7%) 50/326 (15.3%) -1.1 (-6.8 - 4.6)-2.4 (-8.0 - 3.2)63/355 (17.7%) > 10x ULN 197/355 (55.5%) 183/318 (57.5%) 190/326 (58.3%) 2.1 (-5.4 - 9.6)2.8 (-4.7 - 10.2)0.7 (-6.9 - 8.4)> 20x ULN 70/355 (19.7%) 60/318 (18.9%) 64/326 (19.6%) -0.9 (-6.8 - 5.1)-0.1 (-6.1 - 5.9)0.8 (-5.3 - 6.9)AST > 3x ULN 12/355 (3.4%) 11/318 (3.5%) 16/326 (4.9%) 0.1 (-2.7 - 2.8)1.5 (-1.5 - 4.5)1.4 (-1.6 - 4.5)> 5x ULN 93/355 (26.2%) 78/318 (24.5%) 89/326 (27.3%) -1.7 (-8.2 - 4.9)1.1 (-5.6 - 7.8)2.8 (-4.0 - 9.5)> 10x ULN 236/355 (66.5%) 210/318 (66%) 208/326 (63.8%) -0.4 (-7.6 - 6.7)-2.7 (-9.8 - 4.5)-2.2 (-9.6 - 5.1)> 20x ULN 10/355 (2.8%) 15/318 (4.7%) 9/326 (2.8%) 1.9 (-1.0 - 4.8)-0.1 (-2.5 - 2.4)-2.0 (-4.9 - 1.0)Total Bilirubin 2.7 (-4.1 - 9.6)> 2x ULN 117/355 (33%) 81/318 (25.5%) 92/326 (28.2%) -7.5 (-14.3 - -0.6) -4.7 (-11.6 - 2.2)> 5x ULN150/355 (42.3%) 154/318 (48.4%) 141/326 (43.3%)  $6.2 \left(-1.3 - 13.7\right)$ 1.0 (-6.4 - 8.4)-5.2 (-12.9 - 2.5)> 8x ULN 63/355 (17.7%) 63/318 (19.8%) 71/326 (21.8%) 2.1 (-3.9 - 8.0)4.0 (-2.0 - 10.0)2.0 (-4.3 - 8.2)> 2x ULN 123/355 (34.6%) 120/318 (37.7%) 125/326 (38.3%)  $3.1 \left(-4.2 - 10.4\right)$ 3.7 (-3.5 - 10.9)0.6 (-6.9 - 8.1)> 3x ULN 63/355 (17.7%) 57/318 (17.9%) 47/326 (14.4%) 0.2 (-5.6 - 6.0)-3.3 (-8.8 - 2.2)-3.5 (-9.2 - 2.2)ALT or AST and Total Bilirubin ALT > 3x ULN and Total1.4 (-3.2 - 6.1) 293/326 (89.9%) 1.2 (-3.5 - 5.9)0.3 (-4.4 - 4.9)314/355 (88.5%) 285/318 (89.6%) Bilirubin > 2x ULN AST > 3x ULN and Total326/355 (91.8%) 294/318 (92.5%) 301/326 (92.3%) 0.6 (-3.4 - 4.7)0.5 (-3.6 - 4.6)-0.1 (-4.2 - 4.0)Bilirubin > 2x ULN ALT or AST > 3x ULN and 330/355 (93%) 298/318 (93.7%) 304/326 (93.3%) 0.8 (-3.0 - 4.5)0.3 (-3.5 - 4.1)-0.5 (-4.3 - 3.4)

PL=Placebo, T1=Treatment 1, T2=Treatment 2, ALT=alanine aminotransferase, AST=aspartate aminotransferase, ALP=alkaline phosphatase; N = number of applicable subjects in treatment arm; n = actual applicable observed number with values.